^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ENB003

    i
    Other names: ENB003, ENB-003
    Associations

    News

    Trials
    Company:
    ENB Therap
    Drug class:
    Endothelin B receptor antagonist
    Associations

    News

    Trials
    5ms
    CRI-CCTG-0003/IND.240: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Platinum resistant
    |
    Imfinzi (durvalumab) • Loqtorzi (toripalimab-tpzi) • mecbotamab vedotin (BA3011) • ENB003
    1year
    CRI-CCTG-0003/IND.240: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Loqtorzi (toripalimab-tpzi) • mecbotamab vedotin (BA3011) • ENB003
    over1year
    ENBolden-101: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (clinicaltrials.gov)
    P1/2, N=137, Active, not recruiting, ENB Therapeutics, Inc | Phase classification: P1b/2a --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ENB003
    over2years
    ENBolden-101: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=137, Active, not recruiting, ENB Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Mar 2026 | Trial primary completion date: Apr 2024 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ENB003
    almost5years
    ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (clinicaltrials.gov)
    P1b/2a, N=130, Recruiting, ENB Therapeutics, Inc | Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Sep 2023 --> Apr 2024
    Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ENB003